Compare Dishman Pharma with Cadila Healthcare - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DISHMAN PHARMA vs CADILA HEALTHCARE - Comparison Results

DISHMAN PHARMA     Change

Dishman Pharmaceuticals is involved in the manufacture of APIs (active pharmaceutical ingredients), intermediates, quaternary compounds and fine chemicals. Besides this, the company is a significant player in the CRAMS (Contract Research and Manufact... More

CADILA HEALTHCARE 
   Change

Cadila Healthcare is one of the leading players in the Indian pharma market having a presence in both the domestic and international markets. In the international markets, the company had adopted the strategy of competing directly in the generics mar... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DISHMAN PHARMA CADILA HEALTHCARE DISHMAN PHARMA/
CADILA HEALTHCARE
 
P/E (TTM) x 25.1 33.9 73.9% View Chart
P/BV x 3.3 6.0 56.3% View Chart
Dividend Yield % 0.7 0.6 114.5%  

Financials

 DISHMAN PHARMA   CADILA HEALTHCARE
EQUITY SHARE DATA
    DISHMAN PHARMA
Mar-16
CADILA HEALTHCARE
Mar-20
DISHMAN PHARMA/
CADILA HEALTHCARE
5-Yr Chart
Click to enlarge
High Rs374352 106.3%   
Low Rs129207 62.4%   
Sales per share (Unadj.) Rs197.8139.2 142.1%  
Earnings per share (Unadj.) Rs21.211.8 180.2%  
Cash flow per share (Unadj.) Rs34.718.6 187.0%  
Dividends per share (Unadj.) Rs2.003.50 57.1%  
Dividend yield (eoy) %0.81.3 63.4%  
Book value per share (Unadj.) Rs179.9101.4 177.5%  
Shares outstanding (eoy) m80.691,023.74 7.9%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x1.32.0 63.4%   
Avg P/E ratio x11.923.7 50.0%  
P/CF ratio (eoy) x7.215.0 48.2%  
Price / Book Value ratio x1.42.8 50.7%  
Dividend payout %9.429.8 31.7%   
Avg Mkt Cap Rs m20,306286,033 7.1%   
No. of employees `0000.813.4 6.2%   
Total wages/salary Rs m5,35524,145 22.2%   
Avg. sales/employee Rs Th19,252.710,632.7 181.1%   
Avg. wages/employee Rs Th6,459.51,801.2 358.6%   
Avg. net profit/employee Rs Th2,064.1898.5 229.7%   
INCOME DATA
Net Sales Rs m15,961142,531 11.2%  
Other income Rs m2651,139 23.3%   
Total revenues Rs m16,226143,670 11.3%   
Gross profit Rs m4,10324,198 17.0%  
Depreciation Rs m1,0916,965 15.7%   
Interest Rs m9443,418 27.6%   
Profit before tax Rs m2,33414,954 15.6%   
Minority Interest Rs m0288 0.0%   
Prior Period Items Rs m10-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m6243,198 19.5%   
Profit after tax Rs m1,71112,044 14.2%  
Gross profit margin %25.717.0 151.4%  
Effective tax rate %26.721.4 125.0%   
Net profit margin %10.78.5 126.9%  
BALANCE SHEET DATA
Current assets Rs m11,01887,154 12.6%   
Current liabilities Rs m9,51782,694 11.5%   
Net working cap to sales %9.43.1 300.5%  
Current ratio x1.21.1 109.8%  
Inventory Days Days11071 154.7%  
Debtors Days Days3594 37.1%  
Net fixed assets Rs m16,304133,236 12.2%   
Share capital Rs m1611,024 15.8%   
"Free" reserves Rs m12,907102,733 12.6%   
Net worth Rs m14,516103,757 14.0%   
Long term debt Rs m4,18932,146 13.0%   
Total assets Rs m29,805236,866 12.6%  
Interest coverage x3.55.4 64.6%   
Debt to equity ratio x0.30.3 93.2%  
Sales to assets ratio x0.50.6 89.0%   
Return on assets %8.96.5 136.5%  
Return on equity %11.811.6 101.6%  
Return on capital %17.513.7 127.7%  
Exports to sales %24.80-   
Imports to sales %3.70-   
Exports (fob) Rs m3,956NA-   
Imports (cif) Rs m596NA-   
Fx inflow Rs m4,95252,752 9.4%   
Fx outflow Rs m69714,504 4.8%   
Net fx Rs m4,25538,248 11.1%   
CASH FLOW
From Operations Rs m2,78625,054 11.1%  
From Investments Rs m-1,529-10,123 15.1%  
From Financial Activity Rs m-941-10,942 8.6%  
Net Cashflow Rs m3163,989 7.9%  

Share Holding

Indian Promoters % 61.4 74.8 82.1%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 3.7 8.3 44.6%  
FIIs % 12.7 5.9 215.3%  
ADR/GDR % 0.0 0.0 -  
Free float % 22.1 11.0 200.9%  
Shareholders   46,261 44,069 105.0%  
Pledged promoter(s) holding % 35.8 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DISHMAN PHARMA With:   AJANTA PHARMA  FDC  SUN PHARMA  FRESENIUS KABI ONCO.  TTK HEALTHCARE  

Compare DISHMAN PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 257 Points Higher; Tata Steel & Hindalco Among Top Nifty Gainers(Closing)

Indian share markets witnessed positive trading activity throughout the day today and ended higher.

Related Views on News

CADILA HEALTHCARE Announces Quarterly Results (3QFY21); Net Profit Up 40.6% (Quarterly Result Update)

Feb 10, 2021 | Updated on Feb 10, 2021

For the quarter ended December 2020, CADILA HEALTHCARE has posted a net profit of Rs 5 bn (up 40.6% YoY). Sales on the other hand came in at Rs 38 bn (up 4.3% YoY). Read on for a complete analysis of CADILA HEALTHCARE's quarterly results.

CADILA HEALTHCARE 2019-20 Annual Report Analysis (Annual Result Update)

Oct 26, 2020 | Updated on Oct 26, 2020

Here's an analysis of the annual report of CADILA HEALTHCARE for 2019-20. It includes a full income statement, balance sheet and cash flow analysis of CADILA HEALTHCARE. Also includes updates on the valuation of CADILA HEALTHCARE.

CADILA HEALTHCARE Announces Quarterly Results (1QFY21); Net Profit Up 49.3% (Quarterly Result Update)

Aug 21, 2020 | Updated on Aug 21, 2020

For the quarter ended June 2020, CADILA HEALTHCARE has posted a net profit of Rs 5 bn (up 49.3% YoY). Sales on the other hand came in at Rs 36 bn (up 4.1% YoY). Read on for a complete analysis of CADILA HEALTHCARE's quarterly results.

CADILA HEALTHCARE Announces Quarterly Results (2QFY20); Net Profit Down 79.3% (Quarterly Result Update)

Nov 15, 2019 | Updated on Nov 15, 2019

For the quarter ended September 2019, CADILA HEALTHCARE has posted a net profit of Rs 829 m (down 79.3% YoY). Sales on the other hand came in at Rs 34 bn (up 13.7% YoY). Read on for a complete analysis of CADILA HEALTHCARE's quarterly results.

CADILA HEALTHCARE Announces Quarterly Results (1QFY20); Net Profit Down 28.9% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, CADILA HEALTHCARE has posted a net profit of Rs 3 bn (down 28.9% YoY). Sales on the other hand came in at Rs 35 bn (up 20.8% YoY). Read on for a complete analysis of CADILA HEALTHCARE's quarterly results.

More Views on News

Most Popular

Time to Buy Smallcaps?(Fast Profits Daily)

Apr 30, 2021

In this video, I'll show you why I favour smallcaps over the Nifty.

The Next Smallcap Winners(Profit Hunter)

Apr 30, 2021

Price is the only due diligence one might require to buy this business.

Sell in May and Go Away?(Fast Profits Daily)

Apr 28, 2021

Does the concept of selling stocks in the month of May, work in the Indian market?

This Fund Manager Has Taken the World by Storm. Will You Invest With Her?(Profit Hunter)

Apr 26, 2021

Should you invest with this Rockstar fund manager who has outperformed in a big way?

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

DISHMAN PHARMA SHARE PRICE


May 29, 2017 (Close)

TRACK DISHMAN PHARMA

  • Track your investment in DISHMAN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON DISHMAN PHARMA

DISHMAN PHARMA - SUN PHARMA COMPARISON

COMPARE DISHMAN PHARMA WITH

MARKET STATS